Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Smart Eye AB in conjunction with its listing on Nasdaq First North
Mandate

Vinge advises Smart Eye AB in conjunction with its listing on Nasdaq First North

November 11, 2016

Vinge has advised Smart Eye AB in connection with the listing of Smart Eye’s shares on Nasdaq First North.

In connection with the listing, a new issue of not more than 1 750 000 shares was performed whereupon Smart Eye will receive not more than SEK 80 500 000. The offer is directed to the general public and institutional investors. The prospectus was published on 10 November and the first day of trading is 7 December.

Vinge’s team primarily consisted of responsible partner Anders Strid, Magnus Pauli (client relationship), Frida Bäckegren (project manager due diligence and prospectus), Joel Zetterström and Natalie Bäck (IP), Jonas Lindeblad (employment), Björn Nicolai and Karin Wisenius (EU and competition), Victor Ericsson (tax) and company assistant Camilla Andersson.

Related

Vinge advises Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of Bizware

 Vinge has advised the Nordic private equity firm Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of the data analytics and AI firm Bizware AB and its subsidiaries Bizware Lead AB and Bizware Nova AB.
September 11, 2025

Vinge has acted as local counsel supporting lead counsel Latham & Watkins in advising Cadence in connection with its acquisition of Hexagon’s Design & Engineering Business for approx. EUR 2.7 billion

 Cadence (Nasdaq: CDNS) announced it has entered into a definitive agreement to acquire the Design & Engineering business of Hexagon AB, which includes its MSC Software business—a pioneer in engineering simulation and analysis solutions.
September 09, 2025

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025